Research Confirms Hydroxyurea's Impact on Sickle Cell Anemia

Fewer serious complications. Fewer hospitalizations and blood transfusions. Better growth and development. And a markedly lower risk of death from the complications of sickle cell anemia.

These are the benefits documented from 10 years of continuous hydroxyurea treatment provided in the NOHARM trial to a group of young children in Uganda, which has one of the world's largest number of people living with the painful disorder known for causing sickle-shaped red blood cells. These improved outcomes were highlighted May 27, 2026 , in a report published by The New England Journal of Medicine.